Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$63.74 USD
+1.37 (2.20%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $63.73 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
Edwards Lifesciences (EW) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$89.05 | $107.00 | $70.00 | 42.78% |
Price Target
Based on short-term price targets offered by 22 analysts, the average price target for Edwards Lifesciences comes to $89.05. The forecasts range from a low of $70.00 to a high of $107.00. The average price target represents an increase of 42.78% from the last closing price of $62.37.
Analyst Price Targets (22)
Broker Rating
Edwards Lifesciences currently has an average brokerage recommendation (ABR) of 2.32 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on 25 recommendations.
Of the 25 recommendations deriving the current ABR, 10 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 40% and 4% of all recommendations. A month ago, Strong Buy made up 56%, while Buy represented 4%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 14 | 14 | 15 | 12 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 12 | 8 | 8 | 8 | 10 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.32 | 2.00 | 2.00 | 1.96 | 2.16 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/25/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/25/2024 | Evercore Partners | Vijay Kumar | Hold | Hold |
7/25/2024 | Robert W. Baird & Co. | David Rescott | Strong Buy | Hold |
7/25/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
7/25/2024 | Cowen & Co. | Joshua T Jennings | Strong Buy | Hold |
7/25/2024 | Truist Securities | Richard Newitter | Hold | Hold |
7/24/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/10/2024 | SVB Securities | Michael Kratky | Hold | Hold |
6/21/2024 | BTIG | Marie Thibault | Hold | Hold |
6/17/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
5/30/2024 | Goldman Sachs | David H Roman | Not Available | Strong Buy |
5/22/2024 | Not Identified | Not Identified | Hold | Strong Buy |
5/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/26/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Strong Buy | Strong Buy |
4/26/2024 | William Blair | Margaret Kaczor | Strong Buy | Strong Buy |
4/26/2024 | Not Identified | Not Identified | Hold | Hold |
4/26/2024 | Piper Sandler | Adam C Maeder | Hold | Hold |
4/26/2024 | Not Identified | Not Identified | Hold | Hold |
4/26/2024 | Canaccord Genuity | William J Plovanic | Hold | Hold |
4/8/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
10/16/2023 | UBS | Danielle Antalffy | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.32 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 25 |
Average Target Price | $89.05 |
LT Growth Rate | 9.90% |
Industry | Medical - Instruments |
Industry Rank by ABR | 100 of 252 |
Current Quarter EPS Est: | 0.68 |